Delamanid: A new armor in combating drug-resistant tuberculosis.

Article Details

Citation
Copy to clipboard

Xavier AS, Lakshmanan M

Delamanid: A new armor in combating drug-resistant tuberculosis.

J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121.

PubMed ID
25210407 [ View in PubMed
]
Abstract

Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
DelamanidDeazaflavin-dependent nitroreductaseProteinMycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
No
Substrate
Details